Navigation Links
Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue
Date:11/5/2008

ictive of human pharmacokinetics and biological response. In February 2007, a Phase I/II clinical trial of ARX201 was initiated to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of this product candidate in adult patients with growth hormone deficiency following single-dose escalation and repeated dosing.

About Ambrx

Ambrx Inc. is a clinical stage biopharmaceutical company with a broad biologics platform that allows it to create best-in-class protein therapeutics, including improved versions of native proteins and therapeutic antibodies. Its most advanced product candidate, ARX201, is a long-acting human growth hormone drug candidate partnered with Merck Serono that has successfully completed initial clinical trials. The company has further validated its biologics platform through substantial partnerships with Eli Lilly and Company and Merck & Co. Ambrx is advancing a robust portfolio of product opportunities spanning multiple therapeutic areas that are highly optimized for efficacy, safety, and ease of use. For additional information, call 858.875.2400 or visit http://www.ambrx.com.

Media Contacts:

Heidi Chokeir or David Schull

Russo Partners, LLC

(619)814-3512

heidi.chokeir@russopartnersllc.com

david.schull@russopartnersllc.com


'/>"/>
SOURCE Ambrx Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
2. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
3. Avicena Group to Present at Noble Financial Conference
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. CEL-SCI to Present at the Noble Financial Conference
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Strategic Diagnostics Updates Roth Conference Presentation Time
11. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... and NEW ORLEANS , May 22, ... field of regenerative medicine, presented new data generated in ... Group (a leading health economics consultancy) demonstrating the significant ... (DFU) and venous leg ulcers (VLU) place upon the ... this research, which reveal annual costs of up to ...
(Date:5/22/2013)... Express Diagnostics Int’l, Inc. (EDI) , ... pleased to announce a sponsorship agreement with Erebus Motorsport ... distributor of DrugCheck® onsite testing devices, manufactured by EDI. ... Austin 400 May 17-19 in Austin, Texas. , Royal ... each car of the Erebus Motorsport team displaying the ...
(Date:5/22/2013)... -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, ... in vivo production of therapeutic proteins, announced today ... Moderna in early July as its first Chief Information ... in the design and implementation of information systems underlying ... clinical operations and commercial preparedness. John has also been ...
(Date:5/21/2013)... WA (PRWEB) May 21, 2013 Through ... trainings, and funds for lab equipment, 25 organizations will ... and importance of optics and photonics in daily life ... . , The organizations, located in 10 countries, are ... to be awarded by SPIE, the international society ...
Breaking Biology Technology:Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3
... Partners B.V., a leading,GMP biopharmaceutical manufacturer, announced today ... ActoGeniX, drug substance AG011 for use in a,Phase ... ActoGeniX is focused on the development and commercialization ... can,be orally administered. The Company,s lead product AG011 ...
... JERSEY CITY, New Jersey, May 14, Rosetta Genomics (Nasdaq: ... financial results on May 21, 2008, before the,U.S. markets ... a,simultaneous webcast to discuss these results at 4:30 p.m. ... conference call, U.S. and Canadian participants may,dial +1-866-966-5335; international ...
... May 14 Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) ... Rodman & Renshaw 5th Annual Global Healthcare Conference to ... Hotel in Monte Carlo, Monaco.,Jeffrey B. Davis, CEO of ... at 3:10 pm local time, 9:10 am Eastern time ...
Cached Biology Technology:SynCo Bio Partners Completes Manufacture and Release of ActoGeniX' Lead Product for Phase II Clinical Trials 2SynCo Bio Partners Completes Manufacture and Release of ActoGeniX' Lead Product for Phase II Clinical Trials 3Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results 2Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2
(Date:5/21/2013)... A new analysis shows that the nation,s land ... enough algae to produce up to 25 billion gallons ... one-twelfth of the country,s yearly needs. , The findings ... that would be needed to grow significant amounts of ... were published in the May 7 issue of ...
(Date:5/21/2013)... Researchers at USC have found that a class of ... mice. , The drugs, known as "TSPO ligands," ... "We looked at the effects of TSPO ligand in ... stage, and in aged mice when pathology was quite ... Davis School of Gerontology. "TSPO ligand reduced measures of ...
(Date:5/21/2013)... Cancers of all types become most deadly when they ... has reached this stage, it becomes very difficult for ... can develop. Now, researchers at the University of Missouri ... target lymphoma tumor cells wherever they may be in ... in the MU College of Veterinary Medicine, says being ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2
... French . MONTREAL, March 1, 2011 ... rare genetic disease, researchers have discovered how three genes contribute ... understanding of many disorders such as foetal and childhood growth ... result of the Human Genome Project, we know the basic ...
... Cambridge, MASS- When your brain encounters sensory stimuli, such as ... a honking car, that input gets shuttled to the appropriate ... olfactory cortex, while sounds are processed in the auditory cortex. ... follows a predetermined, genetic blueprint. However, evidence is mounting that ...
... Canuel of the Virginia Institute of Marine Science ... Canada, and Mexico who have been awarded a ... As a Leopold Fellow, Canuel will participate in ... Capitol Hilldesigned to promote effective communication of science ...
Cached Biology News:Researchers looking at a rare disease make breakthrough that could benefit everyone 2Researchers looking at a rare disease make breakthrough that could benefit everyone 3MIT-- parts of brain can switch functions 2MIT-- parts of brain can switch functions 3MIT-- parts of brain can switch functions 4VIMS professor selected as Leopold Fellow 2VIMS professor selected as Leopold Fellow 3
... EPS 301 Power Supply, 1. ... maximum.Constant voltage or constant current modes.Single-unit ... precision and reproducibility.Suitable for submarine, mini ... as well as semidry and mini ...
... Supply, 1. 1000 V, 400 mA, ... and constant power modes.Single-unit increments in ... reproducibility.Stores and recalls three protocols.Outstanding choice ... Multiphor II or GenePhor systems. ...
Mouse TrkC Affinity Purified Polyclonal Ab...
Immunogen: Full length M32 fusion protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: